| Literature DB >> 34054699 |
Marco Ciavarro1, Eleonora Grande2, Luigi Pavone1, Giuseppina Bevacqua3, Michelangelo De Angelis1, Paolo di Russo1, Roberta Morace1, Giorgia Committeri2, Giovanni Grillea1, Marcello Bartolo1, Sergio Paolini1,3, Vincenzo Esposito1,3.
Abstract
Introduction: Pre-surgical mapping is clinically essential in the surgical management of brain tumors to preserve functions. A common technique to localize eloquent areas is functional magnetic resonance imaging (fMRI). In tumors involving the peri-rolandic regions, the finger tapping task (FTT) is typically administered to delineate the functional activation of hand-knob area. However, its selectivity may be limited. Thus, here, a novel cue-induced fMRI task was tested, the visual-triggered finger movement task (VFMT), aimed at eliciting a more accurate functional cortical mapping of the hand region as compared with FTT. Method: Twenty patients with glioma in the peri-rolandic regions underwent pre-operative mapping performing both FTT and VFMT. The fMRI data were analyzed for surgical procedures. When the craniotomy allowed to expose the motor cortex, the correspondence with intraoperative direct electrical stimulation (DES) was evaluated through sensitivity and specificity (mean sites = 11) calculated as percentage of true-positive and true-negative rates, respectively.Entities:
Keywords: fMRI; gliomas; hand knob; motor area; pre-surgical planning
Year: 2021 PMID: 34054699 PMCID: PMC8160093 DOI: 10.3389/fneur.2021.658025
Source DB: PubMed Journal: Front Neurol ISSN: 1664-2295 Impact factor: 4.003
Demographic and clinical data: tumor type, localization and EOR.
| 1 | M | 45 | Oligodendroglioma (II) | Yes | R | S1, SPG, precuneus | 93% | M1 R, SMA R, S1 R, MFG R | M1 R, SMA R | - | - | - | - | >1cm | >1cm |
| 2 | F | 38 | Diffuse astrocytoma (II) | Yes | R | SFG, SMA, ACC | 88% | M1 R, SMA R/L, SFG R/L, MFG R | M1 R, SMA R | - | - | - | - | <5mm | <5mm |
| 3 | M | 37 | Anaplastic astrocytoma (II) | Yes | R | M1, PMd, SMG | 86% | S1 R, SMA L/R, M1 L, S1 L, MFG L | M1 R, SMA L | - | - | - | - | <5mm | <5mm |
| 4 | M | 46 | Oligodendroglioma (II) | Yes | R | M1, SMA | 92% | M1 R/L, S1 R, SMA L, MFG R | M1 R | 50% | 100% | 75% | 100% | <5mm | >1cm |
| 5 | F | 70 | Adenocarcinoma (II) | No | L | S1 | 90% | S1 L, M1 L, SMA L, SMA R, M1 R, PMd R, SPG R | M1 R, SMA R | - | - | - | - | >1cm | >1cm |
| 6 | M | 40 | Glioblastoma (IV) | No | R | SFG, IFG, CC | 92% | MFG R | M1 R | - | - | - | - | none | >1cm |
| 7 | F | 55 | Oligoastrocytoma anaplastico (III) | Yes | R | M1, PMd, MFG, IFG | 90% | M1 R, S1 R, M1 L, S1 L | M1 R, SMA L, S1 L | - | - | - | - | >1cm | >1cm |
| 8 | M | 46 | Glioblastoma (IV) | No | L | SM1, SMA, SPG | 76% | M1 L, S1 L, PMd L, IFG L, SMA R, M1 L, S1 L, MFG L, SFG L | M1 R | 28% | 100% | 100% | 87% | <5 mm | <5 mm |
| 9 | F | 52 | Glioblastoma (IV) | No | R | M1, MFG, SFG | 88% | M1 R, S1 R, SMA L, SMA R, M1 L, S1 L, MFG L | M1 R, SMA R | 30% | 100% | 100% | 100% | <5 mm | <5mm |
| 10 | F | 34 | Anaplastic astrocytoma (III) | No | R | M1, SMA, SFG, MFG | 98% | M1 R, S1 R, SMA R, SMA L, MFG L, IFG R, M1 L | M1 R, SMA L, MFG L | 50% | 100% | 100% | 100% | <5mm | <1mm |
| 11 | M | 23 | Ganglioglioma (I) | No | L | SMA | 95% | M1 R/L, S1 R/L, SMA R/L, PMd L, SPG R, SMG R/L | M1 L, SFG L | 37% | 100% | 100% | 100% | <5mm | <1mm |
| 12 | M | 51 | Diffuse astrocytoma (II) | No | L | M1, S1, CC, precuneus | 86% | M1 L, S1 L, M1 R, SPG R, SMG L, AG L | M1 R/L | 66% | 100% | 100% | 100% | <5mm | <1 mm |
| 13 | M | 42 | Glioblastoma (II) | No | R | M1 | 88% | M1 R/L, S1 R/L, SMA R/L, CC L | M1 R/L, SMA R | 57% | 100% | 50% | 100% | <5 mm | <5mm |
| 14 | M | 33 | Anaplastic astrocytoma (IV) | No | L | Thalamus, hippocampus | 77% | MFG L, preSMA L | M1 L, S1 R | >1cm | >1cm | ||||
| 15 | M | 45 | Glioblastoma (IV) | Yes | L | M1 | 84% | M1 R/L, S1 L, SMA L, SPG R | M1 R/L | 71% | 100% | 100% | 100% | <5mm | <5mm |
| 16 | M | 28 | Glioblastoma (V) | Yes | R | M1, SFG, MFG, IFG, insula | 91% | M1 R, S1 R, IPF R, M1 L, SMA L, SFG L, MFG L | M1 R, SMA L, MFG L | - | - | - | - | <5mm | <1mm |
| 17 | M | 77 | Radionecrosis (III) | No | R | SM1, SPG | 70% | SFG R | M1 R, M1 L, SMA L | 100% | 100% | 50% | 100% | - | <5mm |
| 18 | F | 42 | Radionecrosis (III) | No | L | M1 | 85% | S1 L, SPG R/L, SMA R/L, M1 R | M1 R/L | 50% | 100% | 66% | 100% | <5mm | <5mm |
| 19 | M | 46 | Glioblastoma (IV) | No | L | M1 | 86% | M1 R/L, S1 L, SPG R/L, SMA L, PL R | M1 R/L, S1 R | 57% | 100% | 100% | 85% | <5mm | <5mm |
| 20 | M | 30 | Oligodendroglioma (II) | No | R | M1, MFG, IFG | 88% | M1 R/L, S1 R/L, SMA R | M1 R/L, SMA R | - | - | - | - | <5mm | <5mm |
Functional localization of fMRI maps, sensitivity, specificity and minimum distance between functional activation and lesion in both tasks. Tumor location and fMRI activation: M1, motor cortex; S1, sensory cortex; SM1, sensory-motor cortex; SMA, supplementary motor cortex; PMd, dorsal pre-motor cortex; SFG, superior frontal gyrus; MFG, middle frontal gyrus; IFG, inferior frontal gyrus; CC, cingulate cortex; SPG, superior parietal gyrus, IPG, inferior parietal gyrus; SMG, supramarginal gyrus; AG, angular gyrus.
Figure 1Visual-triggered finger movement task (VFMT) protocol (e.g., right hand). Active condition (green dot): patients are instructed to move the corresponding finger when a green dot appears. Passive condition (red dot): patients are instructed to observe without making any movements.
Figure 2Three-dimensional (3D), axial, and sagittal views of the activation maps for both fMRI tasks [finger tapping task (FTT) on the left and visual-triggered finger movement task (VFMT) on the right], elaborated at single-subject level in three exemplar patients for clinical purpose with BrainWave software on T2 MRI sequences. The figure also displays tumor position and its spatial relation with eloquent areas. (A) Patient 10: closer proximity between lesion and FTT vs. VFMT activation map [fMRI specificity: VFMT 100%; FTT 50%; extent of resection (EOR) 98%]. (B) Patient 20: close proximity between lesion and both fMRI maps <5 mm (EOR 88%). (C) Patient 4: a case of tumor recurrence in which VFMT compared with FTT maps has greater reliability (fMRI specificity: VFMT 100%; FTT 50%) and has a major predictive value on EOR (92%).